Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan

This article was originally published in The Tan Sheet

Executive Summary

FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices
Advertisement

Related Content

FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
FDA GMP Plan Stresses Consistency; Systems Approach Ratified By Crawford
FDA GMP Plan Stresses Consistency; Systems Approach Ratified By Crawford

Topics

Advertisement
UsernamePublicRestriction

Register

PS094683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel